Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy - Top-Institutions - MDSpire

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

  • By

  • Peter May

  • Christof Winter

  • Inga Hubrecht

  • Adrian Patenge

  • Selina Strathmeyer

  • Roland Geyer

  • Steffen Heelemann

  • Jan Stratmann

  • Seyer Safi

  • Henriette Klein

  • Folker Schneller

  • Florian Bassermann

  • Aaron Becker von Rose

  • May 18, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Technical University of Munich (TUM) University Hospital
    Technical University of Munich (TUM) University Hospital

    Munich, Bavaria

    Key Differentiators

    • Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #3

    German Center of Lung Research
    German Center of Lung Research

    Lübeck, Schleswig-Holstein

    Key Differentiators

    • Lung Research
    • Oncology

Original Source(s)

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

  • by Peter May, Christof Winter, Inga Hubrecht, Adrian Patenge, Selina Strathmeyer, Roland Geyer, Steffen Heelemann, Jan Stratmann, Seyer Safi, Henriette Klein, Folker Schneller, Florian Bassermann, Aaron Becker von Rose

  • May 18, 2026

Related Content

Imaging features of lung cancer with cystic airspaces: clinical utility, challenges, and perspectives

Multiple ground-glass nodules after lobectomy for multiple primary lung cancer: a case report

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer